Pharmacodynamics Between a Dual Delayed-Release Formulation of Low-Dose Esomeprazole and Famotidine in Healthy Korean Subjects.

Dual delayed-release esomeprazole Famotidine Gastritis Pharmacodynamics Pharmacokinetics Safety

Journal

Clinical therapeutics
ISSN: 1879-114X
Titre abrégé: Clin Ther
Pays: United States
ID NLM: 7706726

Informations de publication

Date de publication:
19 Jul 2024
Historique:
received: 06 03 2024
revised: 17 06 2024
accepted: 17 06 2024
medline: 21 7 2024
pubmed: 21 7 2024
entrez: 20 7 2024
Statut: aheadofprint

Résumé

Gastritis, one of the most common clinically diagnosed conditions, is defined as the infiltration of inflammatory cells into the gastric mucosa. Drugs for gastritis include histamine-2 receptor antagonists and proton pump inhibitors (PPIs), which reduce acidity in the stomach, and antacids, which neutralize acid. Esomeprazole is a PPI for gastroesophageal reflux disease and gastric and duodenal ulcers that has been shown to be safe and effective at a 10 mg dose. Dual-release drugs have not yet been approved for the treatment of gastritis domestically or internationally. In this study, a dual delayed-release (DR) esomeprazole (10 mg), was compared to famotidine (20 mg) to determine its effectiveness in the treatment of gastritis. This study was a randomized, open-label, multiple-dose, 2-treatment, 2-period, 2-sequence crossover study with a 7-day washout between periods. In each period, the subjects were administered one dose of esomeprazole (10 mg) or famotidine (20 mg) for 7 days at each period. The 24-hour gastric pH was recorded after single and multiple doses. The percentage of time (duration%) that the pH was maintained above 4 in the 24 hours after 7 days of repeated dosing was evaluated. The mean percentages of time that the gastric pH was above 4 after multiple doses over 7 days of a dual DR esomeprazole (10 mg) and famotidine (20 mg) was 47.31% ± 14.85% and 23.88% ± 10.73%. Multiple doses of a dual DR esomeprazole (10 mg) showed effective gastric acid secretion suppression compared to famotidine with comparable safety and tolerability. These results provide evidence supporting the clinical use of a dual DR esomeprazole (10 mg) to treat gastritis. gov identifier: NCT04967014.

Identifiants

pubmed: 39033046
pii: S0149-2918(24)00151-6
doi: 10.1016/j.clinthera.2024.06.013
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT04967014']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have indicated that they have no conflicts of interest regarding the content of article.

Auteurs

Young-Sim Choi (YS)

Department of Clinical Pharmacology and Therapeutics, Chungbuk National University College of Medicine and Hospital, Cheong-ju, Republic of Korea.

Jun Gi Hwang (JG)

Department of Clinical Pharmacology and Therapeutics, Chungbuk National University College of Medicine and Hospital, Cheong-ju, Republic of Korea.

Jae-Won Kim (JW)

Chungbuk National University College of Medicine, Cheong-ju, Republic of Korea.

Hyojin Min (H)

Department of Clinical Pharmacology and Therapeutics, Chungbuk National University College of Medicine and Hospital, Cheong-ju, Republic of Korea.

Chang-Hwan Seong (CH)

Department of Clinical Pharmacology and Therapeutics, Chungbuk National University College of Medicine and Hospital, Cheong-ju, Republic of Korea.

Sung Hee Hong (SH)

Hanmi Pharmaceutical Co., Ltd., Seoul, Republic of Korea; Department of Pharmaceutical Medicine and Regulatory Science, Yonsei University, Seoul, Republic of Korea.

Na Young Kim (NY)

Hanmi Pharmaceutical Co., Ltd., Seoul, Republic of Korea.

Min Kyu Park (MK)

Department of Clinical Pharmacology and Therapeutics, Chungbuk National University College of Medicine and Hospital, Cheong-ju, Republic of Korea. Electronic address: mkparkdau@gmail.com.

Classifications MeSH